An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
InfuSystem Announces Pain Management Service Agreement with Leading U.S. Health Care Provider
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
InfuSystem Holdings, Inc. (NYSE American: INFU) has entered into an exclusive three-year agreement with a major U.S. health care provider to offer its InfuBLOCK pain management therapy. This service includes electronic infusion pumps for post-surgical pain management, a 24/7 clinical hotline, and biomedical services. The agreement is expected to drive future revenue, leveraging InfuSystem’s expertise in outpatient care. The company emphasizes its non-narcotic pain management approach, aiming to enhance patient satisfaction while avoiding opioid-related risks.
Positive
Exclusive three-year agreement to provide pain management services, enhancing revenue potential.
Use of electronic infusion pumps promotes patient satisfaction and offers a non-narcotic pain management solution.
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--
InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it has entered into an exclusive three-year pain management agreement with a leading U.S. health care provider with more than 12 million members. As part of the service agreement, the Company will provide InfuBLOCK, its Pain Management Therapy, which includes electronic infusion pumps for continuous peripheral nerve block, a 24/7 clinical hotline, biomedical services and accompanying supplies.
Richard DiIorio, Chief Executive Officer of InfuSystem, said, “We are pleased that InfuSystem has been selected by one of the nation’s leading health care providers to be their exclusive provider of pain management services in the Northern California region including the state of Oregon. I believe our proven track record in providing clinic-to-home solutions that include electronic infusion pumps, allowing our customers more flexibility in delivering accurate medical treatments and our industry leading biomedical services were factors in winning this influential service agreement.
“Our Pain Management Therapy, InfuBLOCK, provides patients with a continuous peripheral nerve block utilizing an electronic infusion pump that will deliver non-narcotic pain medicine after surgery. Our pain therapy program avoids the harmful addictive effects associated with the use of opioid pain medication while controlling the pain resulting in high satisfaction scores from our patients. Additionally, our state-of-the-art electronic infusion pumps provide a superior alternative to elastomeric pumps with much improved accuracy in dosing and significant cost savings for post-surgical recovery.
“This Pain Management service agreement represents an important milestone for InfuSystem, as our team continues to build significant momentum in the adoption of our Pain Management Therapy to drive future revenue. We look forward to a long and successful relationship,” concluded Mr. DiIorio.
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The lead platform is Integrated Therapy Services (“ITS”), providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The ITS segment is comprised of Oncology, Pain Management, Wound Therapy and Lymphedema businesses. The second platform, Durable Medical Equipment Services (“DME Services”), supports the ITS platform and leverages strong service orientation to win incremental business from its direct payer clients. The DME Services segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, our share repurchase program and capital allocation strategy, business plans, objectives and prospects, future operating or financial performance and guidance. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, the uncertain impact of the COVID-19 pandemic, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law, contributions from acquired businesses or new business lines, products or services and other risk factors disclosed in the Company’s most recent annual report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. All forward-looking statements made in this press release speak only as of the date hereof. We do not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law.
Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.
Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700
Source: InfuSystem Holdings, Inc.
FAQ
What is the recent agreement InfuSystem Holdings entered into?
InfuSystem Holdings has signed an exclusive three-year agreement to provide InfuBLOCK pain management therapy to a major U.S. health care provider.
How will the InfuSystem pain management therapy benefit patients?
The InfuBLOCK therapy uses electronic infusion pumps for non-narcotic post-surgical pain management, which helps avoid the risks associated with opioid medications.
What are the key components of the InfuBLOCK therapy?
The InfuBLOCK therapy includes electronic infusion pumps, a 24/7 clinical hotline, and biomedical services for effective pain management.
Which region is InfuSystem providing its services in?
InfuSystem is providing its pain management services in the Northern California region, including Oregon.
What does this agreement mean for InfuSystem's future revenue?
This agreement is expected to drive future revenue growth for InfuSystem as they expand their pain management services.